• EMA committee backed orphan drug designation for Vanda’s imsidolimab to treat generalized pustular psoriasis in the EU.
• FDA is reviewing an imsidolimab Biologics License Application for the same indication, with an action date of Dec. 12, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vanda Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH06400) on July 16, 2026, and is solely responsible for the information contained therein.